<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04241718</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN06477</org_study_id>
    <nct_id>NCT04241718</nct_id>
  </id_info>
  <brief_title>A Feasibility Study on Ultrafiltration and Blood Volume Measurements</brief_title>
  <official_title>A Feasibility Study on Ultrafiltration and Blood Volume Measurements</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nuwellis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daxor Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nuwellis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this feasibility study is to characterize the performance of the Aquadex&#xD;
      FlexFlow® System with the hematocrit (HCT) feature in conjunction with Daxor's blood volume&#xD;
      analyzer (BVA-100). The study will monitor blood volume changes during ultrafiltration (UF)&#xD;
      therapy as a potential means to guide the removal of fluid in subjects hospitalized with&#xD;
      acute decompensated heart failure (ADHF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will measure blood volumes at various time intervals using the BVA-100 for&#xD;
      comparison to corresponding readings of hematocrit (HCT) levels from the Aquadex FlexFlow HCT&#xD;
      sensor. Establishing a correlation between BVA measurements (off-line measurements) and HCT&#xD;
      sensor measurements (on-line measurements) may enable the use of the BVA-100 to guide&#xD;
      ultrafiltration therapy by the Aquadex system for fluid removal.&#xD;
&#xD;
      BVA-100 measurements would be used at baseline to accurately determine patient suitability&#xD;
      for fluid removal and while HCT measurements would be used to monitor blood volume changes&#xD;
      during ultrafiltration therapy, potentially guiding the removal of fluid in subjects&#xD;
      hospitalized with ADHF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. Evaluate changes in blood volume as measured by BVA from before initiation until completion of extracorporeal fluid removal by ultrafiltration</measure>
    <time_frame>Through study procedure completion, average of 2 weeks</time_frame>
    <description>BVA will be used to evaluate changes in blood volume from baseline (i.e., before initiation) until completion of extracorporeal fluid removal by ultrafiltration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2. Evaluate if changes in blood volume, as measured by BVA, correlate with changes in HCT as measured by the device embedded in the Aquadex FlexFlow System ultrafiltration device</measure>
    <time_frame>Through study procedure completion, average of 2 weeks</time_frame>
    <description>A correlation between BVA measured change in blood volume to changes in hematocrit (HCT) as measured by the online HCT sensor embedded in the Aquadex Flexflow system will be determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3. Evaluate the temporal relationship between changes in blood volume, as measured by BVA , and changes in clinical signs and symptoms of fluid overload</measure>
    <time_frame>Through study procedure completion, average of 2 weeks</time_frame>
    <description>Temporal relationship between blood volume change (as measured by the BVA) and changes in clinical signs and symptoms of fluid overload will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>4. Evaluate the temporal relationship between changes in HCT, as measured by Aquadex HCT, and changes in clinical signs and symptoms of fluid overload</measure>
    <time_frame>Through study procedure completion, average of 2 weeks</time_frame>
    <description>Temporal relationship between HCT change (as measured by Aquadex HCT sensor) and changes in clinical signs and symptoms of fluid overload will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>5. Total net fluid loss prior to hospital discharge</measure>
    <time_frame>Daily during study procedure, average of 2 weeks</time_frame>
    <description>The total net fluid removed during the ultrafiltration therapy will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6. Change in urinary sodium concentration from baseline to ultrafiltration completion</measure>
    <time_frame>Through study procedure completion, average of 2 weeks</time_frame>
    <description>Urinary sodium concentration profile from baseline to ultrafiltration completion will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>7. Change in biomarkers from baseline until discharge:</measure>
    <time_frame>through study completion, average of 2 weeks</time_frame>
    <description>Comprehensive Metabolic Panel (CMP)/Basic Metabolic Panel (BMP)&#xD;
N-terminal proB- type natriuretic peptide (NT-proBNP)&#xD;
Troponin-I&#xD;
Urine Nephrocheck</description>
  </primary_outcome>
  <primary_outcome>
    <measure>8. Adverse events of special interest</measure>
    <time_frame>through study completion, average of 1 year</time_frame>
    <description>Acute coronary syndrome&#xD;
Bleeding (requiring blood transfusion or drop of hemoglobin &gt;3g/dl)&#xD;
Catheter-related bloodstream infections&#xD;
Hypotension necessitating intervention</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Acute Decompensated Heart Failure</condition>
  <condition>Fluid Overload</condition>
  <arm_group>
    <arm_group_label>Single-arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No comparator, placebo, or randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aquadex FlexFlow System and BVA-100</intervention_name>
    <description>Aquapheresis therapy with Aquadex FlexFlow System and Blood Volume Measurement with BVA-100</description>
    <arm_group_label>Single-arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or older&#xD;
&#xD;
          2. Subject or legally authorized representative is able to provide appropriate consent to&#xD;
             participate&#xD;
&#xD;
          3. Hospitalized for ADHF with fluid overload as indicated by at least two of the&#xD;
             following:&#xD;
&#xD;
               1. Pitting edema ≥ 2+ of the lower extremities&#xD;
&#xD;
               2. Jugular venous distention &gt; 8 cm&#xD;
&#xD;
               3. Pulmonary edema/pleural effusion on chest x-ray&#xD;
&#xD;
               4. Paroxysmal nocturnal dyspnea or ≥ two- pillow orthopnea&#xD;
&#xD;
               5. Respiration rate ≥ 20 per minute&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable or unwillingness to provide informed consent or to comply with study&#xD;
             requirements&#xD;
&#xD;
          2. Subject who is pregnant&#xD;
&#xD;
          3. Acute coronary syndrome&#xD;
&#xD;
          4. Known bilateral renal artery stenosis&#xD;
&#xD;
          5. Serum creatinine &gt; 3.0 mg/dL at the time of presentation&#xD;
&#xD;
          6. Subject receiving ongoing active treatment with diuretics (up to 2 doses of IV&#xD;
             diuretics are permitted before initiation of ultrafiltration therapy)&#xD;
&#xD;
          7. Systolic blood pressure ≤ 90 mmHg&#xD;
&#xD;
          8. Poor or unattainable central access&#xD;
&#xD;
          9. Has bleeding disorder&#xD;
&#xD;
         10. Contraindications to systemic anticoagulation&#xD;
&#xD;
         11. Allergic to iodine, albumin, or iodinated I-131 albumin&#xD;
&#xD;
         12. Active myocarditis or hypertrophic obstructive cardiomyopathy&#xD;
&#xD;
         13. Severe uncorrected valvular stenosis&#xD;
&#xD;
         14. Complex congenital heart disease&#xD;
&#xD;
         15. Systemic infection&#xD;
&#xD;
         16. Previous organ transplant&#xD;
&#xD;
         17. Enrollment in other clinical trials&#xD;
&#xD;
         18. Life expectancy ≤ 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Rosa Costanzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Edward Hospital Center for Advanced Heart Failure</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Rosa Costanzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Edward-Elmhurst Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pei Gbatu, PhD</last_name>
    <phone>952-657-5822</phone>
    <email>pei.gbatu@nuwellis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Edward Hospital Center for Advanced Heart Failure</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60566</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Rosa Costanzo, MD</last_name>
      <phone>630-932-2165</phone>
    </contact>
    <investigator>
      <last_name>Maria Rosa Costanzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

